Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CAS Clear all
Completed No phase listed Observational

Local Evaluation of Real Relationships

NCT03029221
View directory record Official record
Conditions
Family Relationships, Parent-Child Relationships
Interventions
PREP 8.0 curriculum developed by PREP, Within My Reach curriculum developed by PREP, Within Our Reach 8 Hours curriculum
Other
Lead sponsor
Children's Aid Society in Clearfield County
Other
Eligibility
18 Years and older
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Clearfield, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

NCT01095731
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Tiopronin, Placebo
Drug
Lead sponsor
E. Sander Connolly
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Gainesville, Florida • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 10, 2026, 7:04 AM EDT
Suspended Phase 1Phase 2 Interventional

Cannabichromene Safety in Rheumatoid Arthritis

NCT07087938
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Cannabichromene
Drug
Lead sponsor
Crystal Lederhos Smith
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Not applicable Interventional Results available

Carotid Revascularization Endarterectomy Versus Stenting Trial

NCT00004732
View directory record Official record
Conditions
Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
Interventions
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
106
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 10, 2026, 7:04 AM EDT
Terminated Not applicable Interventional Results available

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

NCT00106938
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions
Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical)
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust

NCT01874834
View directory record Official record
Conditions
Respiratory Depression, Blood Pressure
Interventions
ozone
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Not applicable Interventional

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

NCT02089217
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Procedure · Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 100 Years
Enrollment
2,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
154
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

ASSIST: Treatment for Childhood Apraxia of Speech

NCT03903120
View directory record Official record
Conditions
Childhood Apraxia of Speech
Interventions
ASSIST
Behavioral
Lead sponsor
Temple University
Other
Eligibility
4 Years to 9 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

NCT05107882
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Las Vegas, Nevada • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Acute Ischaemic Stroke

NCT00144014
View directory record Official record
Conditions
Stroke
Interventions
V10153
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • Walnut Creek, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 4 Interventional Results available

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

NCT02579096
View directory record Official record
Conditions
Gout, Chronic Kidney Diseases
Interventions
allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped), Placebo, vehicle control (allopurinol-shaped)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 10, 2026, 7:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

NCT05444894
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 10, 2026, 7:04 AM EDT
Active, not recruiting Phase 1 Interventional

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

NCT04319276
View directory record Official record
Conditions
Glioblastoma
Interventions
Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg), Gallium maltolate (2,000 mg), Gallium maltolate (2,500 mg), Gallium maltolate (recommended phase 2 dose)
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

NCT01002820
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Lexington, Kentucky • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

NCT01137890
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Topiramate for Cocaine Addiction

NCT00685178
View directory record Official record
Conditions
Cocaine Dependence
Interventions
topiramate, Contingency Reinforcement, placebo + NonCR
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 10, 2026, 7:04 AM EDT
Active, not recruiting Not applicable Interventional

The Effects of Caregiver Training on DTTC Treatment Outcomes in CAS

NCT05916222
View directory record Official record
Conditions
Childhood Apraxia of Speech
Interventions
Dynamic Temporal and Tactile Cueing (DTTC)
Behavioral
Lead sponsor
New York University
Other
Eligibility
24 Months to 95 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Hempstead, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Not applicable Interventional Results available

GORE Flow Reversal System and GORE Embolic Filter Extension Study

NCT01343667
View directory record Official record
Conditions
Carotid Stenosis, Constriction, Pathologic, Carotid Artery Diseases, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Arterial Occlusive Diseases, Vascular Diseases, Cardiovascular Diseases, Pathological Conditions, Anatomical
Interventions
Gore Flow Reversal System, Gore Embolic Filter
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Flagstaff, Arizona • Newport Beach, California • San Francisco, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 10, 2026, 7:04 AM EDT
Terminated Phase 4 Interventional Results available

Minimally Invasive Total Knee Replacement - Navigated Versus Non-navigated Study

NCT00733330
View directory record Official record
Conditions
Osteoarthritis
Interventions
Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique, Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation
Device
Lead sponsor
DePuy International
Industry
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Newport Beach, California • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 10, 2026, 7:04 AM EDT
Active, not recruiting Not applicable Interventional

A Randomized Control Trial of Motor-based Intervention for CAS

NCT04642053
View directory record Official record
Conditions
Childhood Apraxia of Speech
Interventions
Dynamic Temporal and Tactile Cuing
Behavioral
Lead sponsor
New York University
Other
Eligibility
29 Months to 95 Months
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 10, 2026, 7:04 AM EDT
Active, not recruiting Not applicable Interventional

Dose Frequency RCT on DTTC in Children With CAS

NCT05675306
View directory record Official record
Conditions
Childhood Apraxia of Speech
Interventions
Dynamic Temporal and Tactile Cueing Treatment
Behavioral
Lead sponsor
Marquette University
Other
Eligibility
30 Months to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effect of Doxycycline in Patients With Amyloidosis

NCT01677286
View directory record Official record
Conditions
Amyloidosis
Interventions
Doxycycline 100 mg po bid x 12 months
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 10, 2026, 7:04 AM EDT
Completed No phase listed Observational

BIONICS - Pharmacokinetics (PK) Trial

NCT02736344
View directory record Official record
Conditions
Heart Disease
Interventions
BioNIR Ridaforolimus Eluting Coronary Stent
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 10, 2026, 7:04 AM EDT
Completed Phase 1 Interventional

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02277197
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions
Ficlatuzumab, Cetuximab
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 10, 2026, 7:04 AM EDT